Foghorn Therapeutics (FHTX) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 5.6% versus a loss of 53.6%. Over five years, NERV leads with a -76.9% price change compared with -85.4% for FHTX. Minerva Neurosciences is the larger company by market cap ($112.2 million vs $109.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | NERV |
|---|---|---|
| Share price | $1.85 | $2.35 |
| Market cap | $109.86M | $112.21M |
| 1-day change | -2.12% | -2.89% |
| YTD return | -65.74% | -41.54% |
| 1-year return | -53.63% | -5.62% |
| 5-year return | -85.43% | -76.87% |
| EPS (TTM) | $-0.98 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $30.91M | — |
| Revenue growth (YoY) | +36.75% | — |
| Net income (latest FY) | $-74.28M | $-293.42M |
| Operating margin | -279.49% | — |
| Net margin | -240.33% | — |
| 52-week high | $7.61 | $12.46 |
| 52-week low | $1.79 | $2.28 |
| Distance from 52-week high | -75.69% | -81.14% |
| Analyst consensus | buy | none |
| Avg. price target upside | +224.32% | +339.57% |
| Average volume | 672.05K | 181.64K |
| Shares outstanding | 59.39M | 47.75M |
| Employees | 106 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed FHTX by 48.0 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
FHTX vs NERV FAQ
Which is bigger, Foghorn Therapeutics or Minerva Neurosciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $112.21M compared with $109.86M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or NERV?
NERV returned -5.62% over the past 12 months, compared with -53.63% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.